Medically reviewed by Dr. Hyun Joon Lee, MD. Board-certified in Family Medicine, Integrative Holistic Medicine, and Obesity Medicine. Founder and Medical Director, SeeBeyond Medicine.
What a plan means when it says TMS is covered
Transcranial magnetic stimulation is an outpatient procedure that places a coil against the scalp and passes a rapidly alternating current through it. The magnetic field changes excitability in the targeted cortical region, with no anesthesia required (CMS LCD L34641).
Coverage does not attach to the machine. It attaches to a diagnosis, a documented treatment history, and a defined number of sessions.
That distinction explains most of the confusion patients bring to a first consultation. A device can be cleared by the FDA for a condition your plan still declines to pay for.
The Medicare policy that governs both states
Medicare does not publish one national rule for TMS. Coverage comes from local coverage determinations written by each Medicare Administrative Contractor.
National Government Services administers Jurisdiction K, which includes New York and Connecticut. Its policy grants limited coverage of TMS for major depressive disorder and states that all other uses are considered experimental and not covered (LCD L34641).
Retreatment sits inside the same document. A patient who met the original criteria and later relapsed may be considered again, provided the earlier course produced greater than 50% improvement on a standard depression rating scale.
What the plan wants documented before it authorizes
Every policy in this space rests on the same logic. TMS is authorized after less intensive treatments have been tried and recorded, not before.
The Jurisdiction K policy asks for a trial of evidence-based psychotherapy at adequate frequency and duration, without significant improvement, documented by standardized rating scales.
It also requires that the order be written by a psychiatrist who has examined you and reviewed your record, with treatment given under that physician's direct supervision.
Commercial policies run in parallel. Aetna's clinical policy bulletin on transcranial magnetic stimulation asks for a psychiatrist-confirmed diagnosis of severe major depressive disorder, documented by standardized rating scales (CPB 0469).
Medication history is where most authorizations are won or lost. That bulletin describes trials of two antidepressants from at least two different classes, each at the maximally tolerated labeled dose for at least eight weeks.
Two policy families, side by side
| Element | Medicare, Jurisdiction K (L34641) | Commercial example (Aetna CPB 0469) |
|---|---|---|
| Covered diagnosis | Major depressive disorder, with all other uses considered experimental | Severe major depressive disorder, confirmed by a psychiatrist |
| Symptom documentation | Standardized rating scales that reliably measure depressive symptoms | Standardized rating scales that accurately measure depressive symptoms |
| Treatment history | Failed antidepressant trials plus a failed trial of evidence-based psychotherapy | Two antidepressants from at least two classes, each at maximally tolerated labeled dose for at least eight weeks |
| Ordering clinician | Psychiatrist who examined the patient, with direct supervision of treatment | Psychiatrist-confirmed diagnosis, with prior authorization forms required |
| Course length | Standard course with taper, extensions reviewed for medical necessity | 30 sessions plus six tapering sessions, longer courses reviewed |
An authorization is a session count
Approvals are written in sessions rather than in months. The standard acute course described across these policies is 36 sessions, roughly 30 delivered five days a week over six weeks, followed by six tapering sessions (CPB 0469).
Sessions beyond that count are reviewed rather than assumed. An extension generally requires documented improvement on a depression rating scale by the end of the initial course.
The codes on your statement follow the same structure. CPT 90867 covers the initial session, including motor threshold determination and cortical mapping, and is reported once per treatment course.
CPT 90868 covers each subsequent delivery, and 90869 covers a subsequent session with motor threshold re-determination. Medicare billing guidance instructs that 90867 not be reported alongside the other two (Article A57647).
Coverage narrows outside major depression
Depression is the indication with the most settled policy. Past that point, terms change by diagnosis and sometimes by coil.
OCD is the clearest example. The FDA granted De Novo clearance in 2018 for deep TMS delivered by an H-coil as an adjunct in adult OCD (DEN170078), and plans that cover OCD frequently name that device type.
Other diagnoses are often labelled experimental in the same policy that covers depression. That labelling settles who pays. It does not settle whether treatment suits your presentation.
SeeBeyond Medicine runs a deep TMS program that treats more than 30 conditions, with a 91% response rate across the program. Candidacy and coverage are assessed as two separate questions during a consultation.
How to check your benefits before the first session
- Ask for the plan's medical policy on transcranial magnetic stimulation by name and number, and request the current version.
- Confirm whether prior authorization is required, who submits it, and how long a determination takes.
- Ask which diagnoses the policy covers, and whether a specific coil or device type is named.
- Ask how many sessions an initial authorization covers and what evidence an extension request needs.
- Ask what you owe: deductible status, coinsurance per session, and your out-of-pocket maximum.
- Record the reference number and the representative's name, then ask for the determination in writing.
Starting treatment before a determination arrives is the most expensive mistake in this process. A denial letter names the criterion that was not met, which tells your clinician exactly what documentation the appeal needs.
Key Takeaways
- Most major commercial plans and Medicare have published coverage policies for TMS in major depressive disorder.
- Plans commonly require documented failed medication trials and a psychiatric evaluation before authorizing treatment.
- Prior authorization is the norm, and the approval covers a defined number of sessions.
- Coverage for conditions outside the cleared indications is far less consistent and often denied.
Related Resources
Start with our complete guide to deep TMS therapy for candidacy, protocol structure, session length, and side effects.
For diagnosis-specific detail, read about deep TMS for anxiety and mood disorders, deep TMS for OCD, deep TMS for PTSD, and deep TMS for insomnia.
Patients whose benefits do not extend to their diagnosis often review ketamine therapy and other options in the same consultation.
Benefits calls are tedious, and they are the part of this process you can control. Twenty minutes on the phone before your first session usually settles the question of cost.
If you would rather have that reviewed alongside your treatment history, deep TMS therapy at SeeBeyond Medicine is delivered under physician supervision at our Scarsdale, NY office in Westchester County and our Greenwich, CT office in Fairfield County.
You can schedule a consultation to review candidacy and documentation together.
This article is for general education and does not replace a medical evaluation. Treatment decisions depend on your history, medications, and lab work. Speak with a qualified clinician before starting, stopping, or changing any therapy.
